CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Plexxikon Gets $15M Investment For Diabetes Drug Development (BioWorld Today)
News | 05. 27. 2004
Plexxikon
Plexxikon Inc. raised $15 million in venture financing to complete a Series B extension round.
